JP2011518883A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518883A5
JP2011518883A5 JP2011507559A JP2011507559A JP2011518883A5 JP 2011518883 A5 JP2011518883 A5 JP 2011518883A5 JP 2011507559 A JP2011507559 A JP 2011507559A JP 2011507559 A JP2011507559 A JP 2011507559A JP 2011518883 A5 JP2011518883 A5 JP 2011518883A5
Authority
JP
Japan
Prior art keywords
medicament
compound
aromatase inhibitor
breast cancer
cdb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011507559A
Other languages
English (en)
Japanese (ja)
Other versions
JP5576362B2 (ja
JP2011518883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041836 external-priority patent/WO2009134723A1/en
Publication of JP2011518883A publication Critical patent/JP2011518883A/ja
Publication of JP2011518883A5 publication Critical patent/JP2011518883A5/ja
Application granted granted Critical
Publication of JP5576362B2 publication Critical patent/JP5576362B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011507559A 2008-04-28 2009-04-27 乳癌を治療するための組成物および方法 Expired - Fee Related JP5576362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4845208P 2008-04-28 2008-04-28
US61/048,452 2008-04-28
PCT/US2009/041836 WO2009134723A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer

Publications (3)

Publication Number Publication Date
JP2011518883A JP2011518883A (ja) 2011-06-30
JP2011518883A5 true JP2011518883A5 (enExample) 2012-06-07
JP5576362B2 JP5576362B2 (ja) 2014-08-20

Family

ID=40758440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507559A Expired - Fee Related JP5576362B2 (ja) 2008-04-28 2009-04-27 乳癌を治療するための組成物および方法

Country Status (21)

Country Link
US (2) US20110053900A1 (enExample)
EP (2) EP2974772A1 (enExample)
JP (1) JP5576362B2 (enExample)
KR (1) KR101349737B1 (enExample)
CN (1) CN102099040B (enExample)
AR (1) AR071419A1 (enExample)
AU (1) AU2009241360B2 (enExample)
BR (1) BRPI0911112A2 (enExample)
CA (1) CA2722637C (enExample)
CL (1) CL2009001011A1 (enExample)
EA (1) EA019224B1 (enExample)
IL (2) IL208845A (enExample)
ME (1) ME01122B (enExample)
MX (1) MX2010011273A (enExample)
MY (1) MY161549A (enExample)
NI (1) NI201000184A (enExample)
NZ (1) NZ589534A (enExample)
TW (1) TWI539953B (enExample)
UA (1) UA101192C2 (enExample)
WO (1) WO2009134723A1 (enExample)
ZA (1) ZA201007648B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157443A1 (en) 2010-06-17 2011-12-22 N.V. Organon (11b,17a)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
HK1200104A1 (en) * 2011-10-04 2015-07-31 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2018106914A1 (en) * 2016-12-09 2018-06-14 Repros Therapeutics Inc. Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
RU2679625C1 (ru) * 2018-11-08 2019-02-12 Ильясов Шамиль Сионович ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
EP0289073B1 (en) 1987-04-24 1991-11-27 Akzo N.V. Novel 11-aryloestrane and 11-arylpregnane derivatives
ATE85342T1 (de) 1987-12-12 1993-02-15 Akzo Nv 11-arylsteroid-derivate.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
CA2139307A1 (en) 1992-07-01 1994-01-20 Donald W. Combs 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
SK282570B6 (sk) * 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE69702450T2 (de) * 1996-05-01 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer 21-substituierte progesteron derivate als antigestagene
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
DK1265911T3 (da) * 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
IN191020B (enExample) * 2000-03-28 2003-09-13 Dabur Res Foundation
US7378406B2 (en) * 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案

Similar Documents

Publication Publication Date Title
JP2011518845A5 (enExample)
CN100349572C (zh) 提高妇女睾酮和相关类固醇浓度的方法
US9370526B2 (en) Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
CN1075375C (zh) 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物
JP2010507685A5 (enExample)
JP2018514593A5 (enExample)
IL292245B1 (en) Polymorphic forms of rad1901-2hcl
JP2010180236A5 (enExample)
SG10201902375XA (en) Dhea compositions for treating menopause
US10695333B2 (en) Pharmaceutical combination comprising LSZ102 and alpelisib
JP2013523683A5 (enExample)
AR071419A1 (es) Composiciones y metodos de tratamiento del cancer de mama
RU2013118325A (ru) Лечение рака молочной железы
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
JP2013500324A5 (enExample)
CO5590926A2 (es) Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama
ES2320662T3 (es) Hormonoterapia restitutiva y tratamiento para la depresion con dienogest.
WO2008121029A2 (en) Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system
US20240316064A1 (en) Use of estretol as a treatment for endometriosis
CN103599108B (zh) 齐墩果酸在制备预防和治疗胆汁淤积症药物中的应用
US20080261929A1 (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20090029954A1 (en) Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
JP7846700B2 (ja) Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
AU2024272667A1 (en) Treatment of breast tissue
WO2025219964A1 (en) Composition for use in the treatment of perimenopausal and post-menopausal symptomatology and in the combined hormonal contraceptive treatment